Serum sickness and serum sickness-like reactions
Mark H Wener, MD
Section Editor:
N Franklin Adkinson, Jr, MD
Deputy Editor:
Anna M Feldweg, MD
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Feb 2018. | This topic last updated: Feb 01, 2018.

INTRODUCTION — The cardinal features of serum sickness are rash, fever, and polyarthralgias or polyarthritis, which begin one to two weeks after the first exposure to the responsible agent and resolve within a few weeks of discontinuation. Although patients may appear very ill and uncomfortable during the acute febrile stage, the disease is self-limited, and prognosis is excellent once the responsible drug is stopped.

This topic review will discuss serum sickness and serum sickness-like reactions (SSLRs), with an emphasis upon the biology and clinical features of serum sickness. A detailed discussion of hypersensitivity vasculitis, which has features similar to serum sickness, is presented separately. (See "Overview of cutaneous small vessel vasculitis" and "Hypersensitivity vasculitis in children".)

BACKGROUND — The term "serum sickness" was introduced by von Pirquet and Schick, who published a book with that title (Die Serumkrankheit) in 1905 [1]. The authors described an illness that developed in some patients after administration of horse serum that had been given as an anti-toxin for the treatment of diphtheria and scarlet fever. They noted that there was a delay between administration of the horse serum and the development of the symptoms of serum sickness, and the delay was shorter if horse serum was administered again at a later time.

TERMINOLOGY — The classic clinical syndrome of serum sickness is caused by immunization of the host (human) by heterologous (nonhuman) serum proteins and subsequent illness caused by formation of immune complexes. However, the term "serum sickness" has also been applied to a variety of different but related syndromes of rash, arthritis, and fever beginning several days to weeks following administration of other types of drugs or in association with some infections. In this topic, we will refer to these related syndromes as "serum sickness-like reactions" and reserve "serum sickness" for the syndrome caused by immune reaction to a heterologous or chimeric protein therapeutic.


Serum sickness — Serum sickness is the prototypic example of the Gell and Coombs "type III" or immune complex-mediated hypersensitivity disease (table 1) [2]. The reaction requires the presence of the antigen, coincident with antibodies directed against the antigen, leading to the formation of antigen-antibody or immune complexes. These should normally be cleared by the mononuclear phagocyte system, although if this system is not functioning well or is saturated by the immune complex load, then excess immune complexes may form in the circulation and deposit in tissues or form directly in the involved tissues. Immune complexes may deposit preferentially in joints because the synovial endothelium is fenestrated (with more permeable pores or slits) and thus is more accessible to proteins and protein complexes, although the reason that immune complexes target specific tissues is not well-understood. Once deposited, the presence of immune complexes in parenchymal tissues triggers an inflammatory response.

Immune complex formation — Following primary immunization with a protein antigen, immunoglobulin M (IgM) antibodies typically begin to develop 7 to 14 days later, and immunoglobulin G (IgG) antibodies appear a few days after IgM [3]. If the foreign protein is still present in the circulation when these antibodies appear, the antigen and antibodies may combine to form immune complexes. The traditional teaching about serum sickness implicated IgG as the predominant immunoglobulin in immune complex formation, although all immunoglobulin classes may be involved. The timing of the development of serum sickness suggests involvement of IgM-containing immune complexes after initial exposure to an antigen. Biopsies of lesional skin in patients with serum sickness from equine anti-thymocyte globulin (ATG) demonstrated IgM, immunoglobulin A (IgA), and immunoglobulin E (IgE), although not IgG, supporting the role of immune complexes containing immunoglobulin classes other than IgG in some cases [4,5].

The ratio of antigen to antibody is critical to the type of immune complex formed. The Heidelberger precipitin curve for the formation of antigen-antibody complexes demonstrates that intermediate-sized or large immune complexes (eg, Ag5Ab5) form in the zone of equivalence, when the ratio of antibody to antigen is optimal (figure 1). These complexes deposit in tissues and are able to activate complement and recruit inflammatory cells more efficiently than small immune complexes. Small immune complexes form under conditions of either excess antigen (Ag) or excess antibody (Ab) (eg, Ag1Ab1, Ag2Ab1, or Ag1Ab2). These small complexes are inefficient at activating complement or binding to low-affinity Fc receptors and cause minimal or no damage if deposited in the tissues.

Complement activation leads to the formation of complement fragments, including C3a, a potent "anaphylatoxin" that causes mast cell degranulation, histamine release, and the development of urticarial lesions. The complement fragment C5a is a potent chemoattractant for neutrophils. (See "Complement pathways".)

Complement activation also facilitates clearance of the immune complexes by coating soluble immune complexes with complement fragments. The complement-coated immune complexes then bind to erythrocytes, which express the receptor for fragments of C3 (complement component 3), on their surfaces. Erythrocyte-bound immune complexes are subsequently cleared by the mononuclear phagocyte system (primarily in the spleen and Kupffer cells of the liver). (See "Regulators and receptors of the complement system".)

Soluble immune complexes, both with and without complement fragments, are also cleared from the circulation by binding to receptors for the Fc portion of IgG (Fc-gamma-R) on cells of the mononuclear phagocyte system. Serum sickness resolves when there is antibody excess or when the antigen is entirely removed from the serum.

Complement-independent mechanisms — Subsequent studies suggested that complement-independent mechanisms were also involved in the pathophysiology of serum sickness. Studies of experimental serum sickness and other immune complex diseases have been performed in mice that were genetically manipulated to disable the complement system and/or remove cellular receptors for the Fc portion of IgG (Fc-gamma-R) [6-9]. These studies revealed that in mice, a functioning complement system is not necessary to generate serum sickness, although intact Fc-gamma-receptors are. Immune complexes in tissues can react directly with Fc-gamma-receptors on neutrophils, mast cells, and phagocytes, leading to release of cytokines, histamine, and other inflammatory mediators and formation of characteristic pathologic lesions, even in the absence of complement. Additional studies have shown that immune complexes acting via the related Fc-gamma-receptor, Fc-gamma-RII, can have an inhibitory and immunomodulatory function [10].

Serum sickness-like reactions — Reactions to a variety of drugs (especially cefaclor and anti-seizure medications) can clinically resemble classic serum sickness but are believed to be caused by different mechanisms. These are called serum sickness-like reactions (SSLRs).

SSLRs also occur following infections (especially streptococcal and some viral infections, such as hepatitis B) and some vaccines [11,12]. The pathogenesis is not well-understood, although it may not depend upon high titers of antibodies and circulating immune complexes, as in classic serum sickness.

Cefaclor – The antibiotic, cefaclor, can cause an SSLR with fever, rash, arthralgias, and possibly other symptoms, typically beginning one to three weeks after initial administration. One study demonstrated that metabolites of cefaclor produced in vitro were found to be toxic for lymphocytes and that the predisposing drug metabolism has a familial distribution and is thus presumptively genetically influenced [13]. This type of reaction in which drug metabolites may have a direct toxic effect on cells and lead to idiosyncratic, delayed drug reactions has been described for other medications, such as trimethoprim-sulfamethoxazole [14,15]. Increased intestinal permeability may contribute to the pathogenesis of SSLRs due to cefaclor [16].

It has been suggested that the term "serum sickness-like disease" should be replaced by "urticaria with arthritis" to describe this drug-induced syndrome [17], although this terminology has not become common. Other terms proposed include "benign iatrogenic vasculitis" and "urticaria-arthralgia syndrome" [18]. (See "Overview of cutaneous small vessel vasculitis".)

Penicillin – An SSLR that occurs days after drug administration may be seen in some patients who receive prolonged, high-dose intravenous penicillin. This may be caused by drug-specific immune complexes, rather than complexes containing heterologous serum proteins. Small drug molecules or their reactive metabolites may serve as haptens that bind covalently to serum proteins, such as albumin, and result in an antibody response either to the hapten or the hapten-protein conjugate [14]. Note that the same patients may develop immediate hypersensitivity, which could be mediated by IgE or IgG, and present with acute urticaria or an anaphylactic/anaphylactoid reaction, as well as a later SSLR. (See "Drug eruptions" and "Overview of cutaneous small vessel vasculitis".)

Hepatitis B – The term "serum sickness" is also used occasionally to describe an immune complex disease associated with infectious agents. As an example, acute hepatitis B infection may present with serum sickness-like features of rash, polyarthritis, and fever in the preicteric phase [19].

ETIOLOGY AND EPIDEMIOLOGY — Serum sickness is more common in adults, while SSLRs are more common in children. Medications and other therapeutic agents are the most common cause of serum sickness and SSLRs. However, the overall incidence of these reactions is not well-documented and varies considerably depending upon the medication in question.

Agents causing serum sickness — Classic serum sickness is caused by administration of a protein antigen from a nonhuman species. Other types of medications and exposures are uncommonly implicated.

The various heterologous proteins that have been associated with serum sickness are shown in the table (table 2). Equine or rabbit anti-thymocyte globulin (ATG) has been implicated in transplant patients [2,20]. In the United States, use of heterologous anti-toxins is relatively infrequent, although still central to the treatment of snakebite or rabies exposure. A meta-analysis reported that serum sickness occurs in 13 percent of patients receiving the sheep hyperimmune Fab anti-venom used in the United States after pit viper snakebites [21]. Series have reported serum sickness after administration of anti-snake venoms to develop in 5.6 to 29 percent of patients [22,23].

Serum sickness has also been reported with several therapeutic murine monoclonal antibodies and chimeric antibodies (made by molecular engineering to combine some protein domains from human immunoglobulins and some of murine derivation) [24,25]. Rituximab (an anti-B cell chimeric mouse monoclonal antibody) has been implicated repeatedly [25-28]. A similar immune-mediated rash, sometimes with features typical of serum sickness, has been reported in up to 3 percent of patients following therapy with infliximab, a chimeric mouse monoclonal antibody against tumor necrosis factor-alpha (TNF-alpha), which is used for Crohn disease or rheumatoid arthritis [24,29,30].

A small number of case reports have implicated humanized monoclonal antibodies, including omalizumab [31], alemtuzumab [32], natalizumab [33], adalimumab [34], and obinutuzumab [35].

Rarely, recurrent exposure to allogeneic human plasma during blood transfusions [36], insect stings [37] or mosquito bites [38], vaccinations [39-42], or allergy immunotherapy extracts [43,44] may cause SSLRs.

Risk factors — Apparent risk factors include the dose, duration, and nature of the heterologous protein, as well as the age of the patient. Hypergammaglobulinemia may also be a risk factor, although this is based upon small numbers of cases.

Dose – Higher doses of the administered agent are more likely than lower doses to result in serum sickness. This observation was made in the original description by von Pirquet, who noted that serum sickness developed in over 80 percent of patients receiving doses greater than 100 mL of anti-serum, while only 10 to 15 percent of patients receiving less than 20 mL of anti-serum were afflicted. Similarly, higher doses of equine botulinum anti-toxin and anti-snake venom were found to be more likely than lower doses to lead to serum sickness [45,46]. The influence of dose was not found in another study of serum sickness due to snakebite anti-venom serum [23]. (See "Snakebites worldwide: Clinical manifestations and diagnosis" and "Evaluation and management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States".)

Nevertheless, even small doses of foreign protein may lead to the development of serum sickness in some situations. Some patients, for example, exposed to small amounts of bovine serum albumin administered during embryo transfer in the process of in vitro fertilization have been found to develop a serum sickness reaction to the bovine serum used for in vitro culture of the ova [47]. Similarly, it has been postulated that some of the reactions to human diploid cell rabies vaccine may arise from reactions to the fetal bovine serum used to grow the cells in tissue culture (table 2) [40].

Dosing schedule – Serum sickness can develop after a patient's initial exposure to a drug or after subsequent exposures [48].

Intermittent exposure to a heterologous protein is associated with higher rates of SSLRs compared with continuous exposure, as illustrated by the following reports [24,49]:

Twenty-five percent (10 of 40) of patients reinfused with infliximab following a long dosing hiatus developed a severe delayed reaction requiring glucocorticoid therapy [24]. These reactions typically occurred 3 to 12 days following the second or third infusion.

Delayed SSLRs (arthralgias and fevers) developed in 15 percent of 52 adults given intermittent courses of infliximab therapy for Crohn disease [49]. Delayed administration (greater than 20 weeks) of a second dose was associated with a higher risk of reactions. In this study, reactions were more likely to occur after a second dose than after subsequent doses of infliximab and were less likely to occur if the time between administration of the first and second doses was less than 20 weeks. (See "Overview of biologic agents and kinase inhibitors in the rheumatic diseases" and "Infliximab in Crohn disease".)

Properties of the causative agent – Some agents are more likely to cause serum sickness than others. As examples, 85 percent of patients developed serum sickness in response to ATG administered daily for 10 to 14 days for bone marrow failure in one series [5]. Forty to 80 percent of patients given anti-venoms for snakebite may develop serum sickness [50-53]. In contrast, a report from the Ukraine stated that anti-diphtheria serum caused serum sickness in only 1.5 percent of 2247 patients [54].

Age of patient – For some etiologies, adults may be at higher risk for serum sickness than children. Serum sickness in response to human and equine anti-rabies globulins was found in fewer than 0.5 percent of children under the age of 10 years in a series of 72,000 patients (adults and children) receiving these preparations [55]. Although unusual in children overall, SSLRs have been reported as a relatively common etiology of acute arthritis in children under 16 years of age [17]. (See "Evaluation of the child with joint pain and/or swelling".)

Hypergammaglobulinemia and cryoglobulinemia – The development of serum sickness following treatment with rituximab may be more likely in patients with hypergammaglobulinemia [48]. Patients with hepatitis C-related mixed cryoglobulinemia vasculitis are at risk for serum sickness after rituximab infusion [56].

Previous animal and insect exposure – Patients with prior exposure to rabbits may be at an increased risk of developing serum sickness after receiving rabbit ATG [20], and multiple repeated insect stings and bites may predispose to the rare phenomenon of serum sickness after stings [38].

Factors that reduce risk — Chemical modifications of the heterologous protein can decrease the risk of serum sickness reactions to some agents:

The risk of serum sickness reactions after administration of Fab fragments of sheep anti-digoxin to treat a digitalis overdose is very small because Fab fragments rather than intact antibodies are administered and because the dose administered tends to be very low.

Purification and enzymatic partial digestion of equine rabies anti-toxin (hyperimmunoglobulin) appear to decrease the risk of a reaction to that agent [57].

Use of Fab fragments of sheep anti-venom to treat Crotalidae snakebites is associated with lower rates of serum sickness and milder symptoms when reactions do occur, although the risk is not completely eliminated [58-60]. These fragments do not activate complement or bind to the Fc-gamma-receptor, because they lack the Fc fragment, which contains the binding sites for complement and Fc-gamma-receptors. (See "Evaluation and management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States", section on 'Discharge instructions'.)

Another factor that may reduce the risk of serum sickness reactions is the concomitant administration of immunosuppressant drugs. It has been reported that administration of methotrexate prevents development of cutaneous vasculitis in treating rheumatoid arthritis patients with repeated doses of infliximab. However, the mechanism of this interaction has not been characterized, and the safety of this approach in general is not known. (See "Overview of biologic agents and kinase inhibitors in the rheumatic diseases" and 'Preventing recurrence' below.)

Agents causing serum sickness-like reactions — Drugs and vaccines are the leading causes of serum sickness-like reactions (SSLRs).

Drugs — Drugs, particularly antibiotics, are the leading cause of SSLRs. Penicillin, amoxicillin, cefaclor, and trimethoprim-sulfamethoxazole are most commonly implicated, although many drugs have been associated with these reactions (table 3) [27,61-66] (see "Drug eruptions"). Viral infections can cause fever, rash, and arthralgias that mimic SSLRs.

In children, SSLRs are about 15-fold more likely with cefaclor than with other cephalosporins or amoxicillin, even though all are structurally similar beta-lactam antibiotics [67-69]. Among children under five years of age treated with cefaclor, SSLRs have been reported to occur in 0.024 to 0.2 percent of courses [18]. About 50 percent of patients were hospitalized, although the outcomes were universally favorable.

Vaccines — Administration of rabies vaccine preparations have been associated with SSLRs [70-73]. Rarely, commonly administered immunizations, such as influenza, tetanus, and pneumococcal vaccines, have been reported to cause SSLRs [74,75].

CLINICAL MANIFESTATIONS — The most common symptoms of serum sickness are dermatitis, fever, malaise, and polyarthralgias or polyarthritis.

Temporal course — Signs and symptoms of serum sickness begin one to two weeks after the first exposure to the responsible agent. In patients who have been previously exposed to the causative drug, the syndrome starts earlier (ie, within one to seven days of receiving the inciting agent), and the illness has a more severe and "explosive" onset. If the patient still has immunoglobulin G (IgG) or immunoglobulin E (IgE) antibodies resulting from a previous exposure when that drug or serum is given again, an immediate reaction (such as an acute anaphylactoid reaction) may occur, giving rise to a mixed clinical picture that has features of both anaphylaxis and serum sickness. In theory, this could result from activation of mast cells or leukocytes by complement split products (ie, the anaphylatoxins C3a and C5a) via IgG immune complexes or direct mast cell activation via IgE cross-linking. (See "Anaphylaxis: Emergency treatment" and "Complement pathways".)

Serum sickness resolves when the causative agent is removed from the system. Typically, fever resolves within a few days of removal of the responsible agent, followed by resolution of rheumatic symptoms. Previous skin lesions may linger for longer periods. Symptoms typically resolve within two weeks of removal of the offending agent, although in unusual cases, symptoms can persist for as long as two to three months [1]. The course of illness may be protracted if the culprit agent has been administered as a depot or sustained release form [61].

Fever — Virtually all patients diagnosed with serum sickness develop fever, which is usually >38.5°C (>101.3°F). The fever of serum sickness is characterized by high spikes that return to normal within the same day. Rigors are unusual. The fever is remittent but has no predictable temporal pattern. Malaise preceding and during the fever is common.

Dermatologic findings — The cutaneous manifestations of serum sickness are variable. Almost all patients diagnosed with serum sickness develop a pruritic rash, which is often the earliest clinical feature. The dermatitis generally lasts a few days to two weeks after the causative agent is stopped. The mucous membranes are not involved, which can be a useful feature in distinguishing serum sickness from clinically similar conditions, especially Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). There may be urticarial lesions, which are typically longer-lasting than hives from other causes (picture 1 and picture 2 and picture 3 and picture 4). Individual lesions may last days to weeks.

The rash often starts in the region around the injection site if a drug was administered locally by intramuscular or subcutaneous injection (as was typical for equine diphtheria anti-toxin described by von Pirquet). This was first described in patients receiving horse anti-thymocyte globulin (ATG) administered as part of an immunosuppressive regimen used to treat aplastic anemia and other forms of bone marrow failure [2,4,5]. It may also start in the anterior lower trunk, groin, periumbilical, or axillary regions and spread to involve the back, upper trunk, and extremities. Skin changes may be prominent at the lateral aspect of the feet and hands, at the junction of the sole and side of the foot, or the border between the palm and dorsal skin of the fingers and hands (picture 5 and picture 6).

Other skin manifestations may include palpable purpura, morbilliform eruptions, papules, or maculopapular lesions. Palmar erythema, livedo reticularis, and periungual hemorrhages have also been described. Frank vasculitis is uncommon. Ulcers, secondary infection, or scarring do not occur. (See 'Differential diagnosis' below.)

Rheumatic features — Arthralgias are a characteristic but inconsistent feature of serum sickness, appearing in approximately two-thirds of patients. The joints commonly involved include the metacarpophalangeal joints, knees, wrists, ankles, and shoulders, although pain in the spine is also described. Pain in the jaw and temporomandibular joints is reported, particularly with serum sickness caused by ATG [20,56]. Myalgias in the arms and thighs may also occur.

While tenderness to palpation and movement are common and may be severe, swelling and erythema due to arthritis occur in only a minority of patients. The joint involvement tends to occur after the rash has started and resolves before the rash has cleared.

Less common features — Other less common features of serum sickness include [5]:

Nonspecific headache and blurred vision

Edema (including facial or peripheral edema)

Lymphadenopathy (particularly in regional lymph nodes draining the site of injection of the protein antigen/immunogen)


Gastrointestinal symptoms, including bloating, cramps, nausea, and diarrhea and occasionally melena

Anterior uveitis

Peripheral neuropathy, including Guillain-Barré syndrome – Rarely, the inflammatory process of serum sickness may be sufficiently intense to lead to long-term sequelae, such as persistent neuropathy, but the inflammatory process itself is self-limited if the offending antigen is removed



Differences in serum sickness-like reactions — Serum sickness-like reactions (SSLRs) are generally less severe than classic serum sickness. They typically involve a constellation of signs and symptoms, which can include arthralgias, lymphadenopathy, and urticarial rash, with or without fever [76]. When fever is present, it is typically low-grade. In a prospective study of children treated with cefaclor, 42 developed SSLRs, with symptoms beginning 5 to 10 days following oral administration in 90 percent [16]. Symptoms frequently resolve within 3 to 4 days but may last for two weeks, even with glucocorticoid treatment [76].

Patients with SSLRs usually present with urticarial lesions that often start in the flexures that then become generalized. These eruptions are frequently initially mistaken for acute urticaria, but in contrast to acute urticaria, individual lesions remain for greater than 24 hours. The skin lesions typically gradually expand, leaving central clearing or central faint purpura, which are usually most evident on the abdomen or lower legs (picture 7A-C).

Other signs include erythema and edema of the hands and feet, although this is not common. Children with SSLRs may present with acute onset of joint pain, often leading to inability to walk.


Laboratory tests — We suggest that all patients who appear moderately or severely ill and patients with any severity of illness who are not taking a medication that can be readily implicated as the culprit, be evaluated with the following laboratory tests:

Complete blood count and differential – In serum sickness, complete blood count (CBC) with differential frequently demonstrates neutropenia, with development of reactive, plasmacytoid lymphocytes. Mild thrombocytopenia may occur. Eosinophilia may be present but is not prominent.

Erythrocyte sedimentation rate and C-reactive protein – These acute-phase reactants are elevated during active serum sickness.

Urinalysis – During serum sickness, urinalysis demonstrates mild proteinuria in about one-half of patients. Those with proteinuria may also develop transient mild hematuria without cellular casts. In contrast, urinalysis is usually normal in SSLRs [16].

Serum chemistries, including blood urea nitrogen, creatinine, and liver function tests – Occasionally in serum sickness, the serum creatinine is elevated up to about twice the baseline value, but renal dysfunction tends to resolve within a few days. Overt glomerulonephritis is rare. Hypoalbuminemia may be present in patients with edema. In contrast, renal and other systemic organ involvement is unusual in SSLRs due to medications.

Testing to exclude infection — An important early goal of the evaluation is the exclusion of infectious causes, such as hepatitis B. Testing for specific infectious diseases should be performed if indicated by the history or physical examination or if a patient has an unusually long disease course that persists after stopping the medication suspected of causing serum sickness. (See 'Differential diagnosis' below.)

Other laboratory findings — Other tests, such as complement studies and skin biopsy, are sometimes performed in patients suspected of having serum sickness or SSLRs, although these are not recommended as part of the routine evaluation.

Complement studies, including CH50, C3, and C4 – During severe episodes, complement measurements, including C3, C4, and total hemolytic complement (CH50), are depressed, reflecting complement consumption. Measures of circulating immune complexes, including the fluid-phase C1q-binding test and the Raji cell assay, are typically elevated [5,19]. The changes in complement and immune complex levels do not closely parallel the clinical course of serum sickness, and these tests are not routinely recommended as part of the laboratory evaluation. (See "Overview and clinical assessment of the complement system".)

Skin biopsy – Skin biopsies are not usually necessary or helpful in confirming the diagnosis, since the findings are variable and not specific for serum sickness. In most cases, findings are similar to those seen in patients with urticaria:

Mild perivascular infiltrates consisting of lymphocytes and histiocytes, in the absence of vessel necrosis, were the most typical findings in skin biopsies of patients who developed serum sickness from equine anti-thymocyte globulin (ATG) [4]. Immunofluorescence microscopy demonstrated immunoglobulin M (IgM) and C3, although no immunoglobulin G (IgG). It is possible that patients receiving ATG are not representative of all patients with serum sickness, because they are immunosuppressed by both ATG and glucocorticoids and often are neutropenic because of their underlying hematologic problem.

Leukocytoclastic vasculitis with neutrophilic involvement and fibrinoid necrosis has been reported in a minority of patients with serum sickness. Immunohistochemical or immunofluorescence staining with specific antibodies may reveal the presence of IgG and C3 within the walls of small arterioles and capillaries. (See "Overview of cutaneous small vessel vasculitis".)

A neutrophil-rich urticarial pattern has been reported with SSLRs [77].

DIAGNOSIS — The diagnosis of serum sickness is usually made clinically, based upon the characteristic pattern of acute or subacute onset of a compatible rash, fever, and severe arthralgias and myalgias disproportionate to the degree of swelling, all occurring after exposure to a potential offending agent. Laboratory findings should be consistent with the diagnosis.

The diagnosis of SSLRs is made in the same manner. Identification of the offending agent can be difficult if patients are on multiple medications that can be associated with SSLRs.

DIFFERENTIAL DIAGNOSIS — The differential diagnosis of serum sickness and SSLRs includes viral illnesses with exanthems, hypersensitivity vasculitis, acute rheumatic fever, acute meningococcal or gonococcal infection, systemic juvenile idiopathic arthritis (formerly called Still's disease), and other types of drug reactions. In children, Kawasaki disease and acute annular urticaria are additional possibilities.

In patients of any age

Viral exanthematous infections – Viral infections can cause fever, rash, malaise, myalgias, and arthralgias, although joint complaints are usually not as prominent as in serum sickness. Viral infections that cause exanthems or urticaria can be particularly difficult to differentiate from serum sickness. The presence of mucosal lesions or pharyngeal lesions, which may be seen with viral infections, is atypical of serum sickness. Increasing transaminases suggest the possibility of preicteric hepatitis B infection, which can be confirmed by specific tests for hepatitis B virus. (See "Clinical manifestations and natural history of hepatitis B virus infection".)

The emerging viral disease, chikungunya may be confused with serum sickness. Typically, the pain associated with the arthritis of chikungunya is more severe and disabling than the arthralgias in serum sickness, and headache is typical in chikungunya but not common in serum sickness. (See "Chikungunya fever".)

Dengue fever also may present with fever, arthralgia, and rash, but the cutaneous finding are more hemorrhagic and petechial than in serum sickness, and myalgias are more prominent than arthralgias. Zika virus infection may present with fever, rash, and arthralgias, but conjunctivitis is more likely in Zika infection. Travelers or residents of areas with these disorders should have appropriate serologic or nucleic acid-based testing to rule out these infections. (See "Dengue virus infection: Clinical manifestations and diagnosis" and "Zika virus infection: An overview".)

Hypersensitivity vasculitis and urticarial vasculitis – The pathogenesis of hypersensitivity vasculitis, urticarial vasculitis, and serum sickness all involve pathogenic formation of immune complexes, and both clinical and pathogenic overlap occurs between these conditions. A number of drugs (eg, penicillins) can cause both SSLRs and hypersensitivity vasculitis. Most patients with serum sickness do not develop frankly vasculitic rashes. Arthralgias and arthritis are typically more prominent in serum sickness than in primary vasculitis, although they may be present in both.

Urticarial vasculitis can be associated with systemic lupus erythematosus or can be a primary disorder, often associated with hypocomplementemia and autoantibodies to the complement component C1q as part of the hypocomplementemic urticarial vasculitis syndrome. (See "Urticarial vasculitis".)

Children with immunoglobulin A vasculitis (IgA vasculitis; formerly called Henoch-Schönlein purpura) typically have prominent bloody diarrhea, a petechial rash, proteinuria, and arthritis, with IgA deposits present in the skin and renal biopsies. (See "Hypersensitivity vasculitis in children" and "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis".)

Patients with chronic hepatitis C may have the mixed cryoglobulinemia syndrome, but those patients typically have recurrent vasculitic palpable purpura and frequently have overt findings of glomerulonephritis. (See "Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)".)

Acute rheumatic fever – Patients with acute rheumatic fever typically have migratory arthritis with prominent joint swelling, in contrast to the simple arthralgias that characterize serum sickness. Cardiac murmurs, carditis, and elevated serologic tests consistent with a recent streptococcal infection also suggest acute rheumatic fever. (See "Acute rheumatic fever: Clinical manifestations and diagnosis".)

Scarlet fever – The characteristic scarlatiniform rash of scarlet fever is rarely associated with serum sickness, and the "strawberry tongue" of scarlet fever is not seen in serum sickness (picture 8). In scarlet fever, the rash occurs along with the acute streptococcal infection on the second or third day of illness, whereas the onset of the rash and fever of serum sickness occurs at least several days after exposure to the inciting drug. (See "Complications of streptococcal tonsillopharyngitis".)

Lyme disease – The erythema migrans rash of Lyme disease is distinct from the rash of serum sickness (picture 9). The typical monoarthritis of the knee seen in Lyme disease is not typical of serum sickness. A history of tick exposure would suggest the diagnosis of Lyme disease. (See "Lyme disease: Clinical manifestations in children", section on 'Erythema migrans' and "Clinical manifestations of Lyme disease in adults", section on 'Early localized disease'.)

Disseminated gonococcemia or meningococcemia – Patients with meningococcemia are usually acutely ill with findings of meningitis. The skin findings of patients with these conditions often include cutaneous pustules or purpuric lesions containing the organism, whereas pustules are not seen in serum sickness (picture 10). Patients with disseminated gonococcal infection can have a localized septic arthritis with swelling atypical of serum sickness but can also have polyarthritis with painful periarticular swelling that can be confused with the findings of serum sickness. (See "Clinical manifestations of meningococcal infection" and "Disseminated gonococcal infection".)

Reactive arthritis – Both reactive arthritis (formerly known as Reiter syndrome) and serum-sickness patients develop fever and joint pain. Mucosal involvement (urethritis, stomatitis) and eye inflammation are common in reactive arthritis and not in serum sickness. The skin lesions associated with reactive arthritis, such as circinate balanitis, are distinct from the typical skin findings of serum sickness. Joint swelling and the development of chronic or recurrent arthritis are prominent in reactive arthritis, although not in serum sickness. (See "Reactive arthritis".)

Drug reaction with eosinophilia and systemic symptoms – In both drug reaction with eosinophilia and systemic symptoms (DRESS) and serum sickness, fever and rash are characteristic, and lymphadenopathy may be prominent. The typical urticarial rash of serum sickness is not seen in DRESS. A morbilliform rash present in the early phases of DRESS may be similar to the morbilliform pattern sometimes seen in serum sickness, but the rash of DRESS usually becomes confluent and very red and results in sloughing and peeling that are not seen in serum sickness. Arthralgias, typical of serum sickness, are not seen in DRESS. The prominent eosinophilia and elevated transaminases that are characteristic of DRESS are not seen in serum sickness. (See "Drug reaction with eosinophilia and systemic symptoms (DRESS)".)

Other drug reactions – Other drug reactions that may mimic serum sickness or SSLRs include nonspecific exanthems, urticaria, and generalized hypersensitivity reactions. The development of an immunoglobulin E (IgE)-mediated drug allergy can cause the onset of urticaria during a course of therapy. The concomitant presence of other allergic symptoms (such as throat tightness, wheezing, or acute anaphylaxis) may help elucidate the underlying process. If the culprit drug was penicillin or another beta-lactam drug, then skin testing for IgE-mediated drug allergy may be possible after the reaction has resolved. (See "Penicillin allergy: Immediate reactions".)

Erythema multiforme – The presence of target skin lesions and involvement of the palms, soles, and mucosal surfaces are characteristic features of erythema multiforme (picture 11). None of these are typical of serum sickness. White blood cell counts and liver enzymes may be elevated in erythema multiforme but are not in serum sickness or SSLRs. Arthralgias are generally not prominent in erythema multiforme. (See "Pathogenesis, clinical features, and diagnosis of erythema multiforme" and "Fever and rash in the immunocompetent patient".)

Stevens-Johnson syndrome – Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are potentially fatal drug hypersensitivity reactions that typically begin suddenly, with high fever, vesicular or bullous lesions on an erythematous background, and systemic illness (picture 12). In the earliest stages, these reactions could be confused with SSLRs, although the later lesions of these severe reactions are distinct, and the mucous membranes are not involved in serum sickness or SSLRs. Prompt discontinuation of possible culprit drugs is the most important immediate intervention in SJS and TEN. (See "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis".)

Systemic juvenile idiopathic arthritis – Systemic juvenile idiopathic arthritis (formerly called Still's disease) may present with fever, arthralgias, oligoarthritis or periarthritis, and rashes. The rash of systemic juvenile idiopathic arthritis is classically evanescent, appearing during the febrile phase of the circadian variations in body temperature associated with systemic juvenile idiopathic arthritis and then fading within a few hours (picture 13). In contrast, the rash of serum sickness is morphologically different and is usually more persistent. Systemic juvenile idiopathic arthritis is likely to continue or recur without treatment, whereas serum sickness resolves within a few weeks of discontinuing the offending agent. The extreme elevations in serum ferritin that are characteristic of systemic juvenile idiopathic arthritis are not seen in serum sickness. (See "Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis" and "Clinical manifestations and diagnosis of adult Still's disease".)

Sweet syndrome – Sweet syndrome (acute febrile neutrophilic dermatosis) presents with high fevers and skin rash, and arthralgias and myalgias may also be prominent. The skin lesions of Sweet syndrome are painful or associated with a burning sensation and are vesicular, nodular, or plaque-like, which are all features that differ from the usual pruritic rash of serum sickness. The drugs that trigger Sweet syndrome in some cases are not those typically responsible for serum sickness or SSLRs. Skin biopsies, often used to diagnosis Sweet syndrome, demonstrate prominent neutrophilic infiltrate that differs from findings typically seen in serum sickness. (See "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis" and "Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis".)

Other considerations in children

Autoinflammatory syndromes – Autoinflammatory syndromes (such as familial Mediterranean fever, chronic infantile neurologic, cutaneous, and articular [CINCA] syndrome, and neonatal-onset multisystem inflammatory disorder [NOMID]) present with fever, rashes, and arthritis. However, these are recurrent disorders, rather than the acute self-limited reaction of serum sickness. (See "Periodic fever syndromes and other autoinflammatory diseases: An overview".)

Kawasaki disease – The presentation of fever, rash, and hand edema in children with Kawasaki disease can mimic serum sickness. However, Kawasaki disease can involve peripheral extremity changes, including erythema of palms or soles or edema of hands or feet (during the acute phase) and periungual desquamation (during the convalescent phase), which are different from the polyarthritis and arthralgias of serum sickness. In addition, prominent mucosal disease in the mouth and conjunctiva are typical of Kawasaki disease and unusual in serum sickness. (See "Kawasaki disease: Clinical features and diagnosis".)

Acute annular urticaria (urticaria multiforme) – Acute annular urticaria, also known as urticaria multiforme, is a self-limited urticarial hypersensitivity eruption that primarily occurs in infants and very young children [78-80]. Lesions appear on the face, trunk, and extremities as annular erythematous plaques with central clearing or dusky blue centers. Unlike SSLRs and erythema multiforme, the duration of individual lesions does not exceed 24 hours. Myalgias and arthralgias are absent. Pruritus is typically present. Other associated findings may include angioedema of the face or acral areas, dermatographism, and low-grade fever. Viral or bacterial infections, antibiotics, and vaccinations have been proposed as potential triggers. The disorder is treated with antihistamines and discontinuation of a triggering medication, if present. (See "Approach to the patient with annular skin lesions".)

TREATMENT — There are no evidence-based guidelines or controlled trials upon which to base therapy recommendations. The approach here is based upon the author's experience, as well as case reports and series in the literature [18,48,50,81,82].

To determine common practices, a retrospective chart review examined the management of children presenting with reactions to cefaclor by emergency department pediatricians [81]. The most common treatment for SSLRs was discontinuation of the culprit drug, combined with the prescription of both antihistamines and glucocorticoids.

Withdrawal of culprit agent — Many patients with minimal disease do not require treatment other than withdrawing the offending agent. Typically, fever and arthralgias resolve and new skin lesions stop forming within 48 hours of this intervention. Clinical symptoms may last longer for drugs with delayed clearance, although clearance of drugs is usually accelerated by the antibodies that also cause the serum-sickness reaction.

Symptomatic treatment — Antihistamines may be sufficient for patients with pruritus and mild rash. Antihistamine dosing is discussed separately. (See "New-onset urticaria", section on 'H1 antihistamines'.)

Nonsteroidal anti-inflammatory agents and analgesics may be used for low-grade fever and arthralgias.

Glucocorticoids — Patients with higher fever (eg, temperature >38.5°C [>101.3°F]), more severe arthritis and arthralgias, or more extensive rashes, including extensive vasculitic rashes, may be treated with short courses of glucocorticoids. The utility of glucocorticoids in the treatment of serum sickness and SSLRs is based upon case reports and small observational series. These agents are usually administered orally (eg, prednisone at 0.5 to 1 mg/kg per day) [27,61,63]. Sometimes even higher doses are used. Occasionally, patients who are very uncomfortable or who appear acutely ill may be treated with intravenous methylprednisolone in the range of 1 to 2 mg/kg per day in one or two divided doses [48,83]. Glucocorticoids can frequently be rapidly tapered, with the total duration of therapy less than one week. However, withdrawal will occasionally result in recurrence of the symptoms, in which case glucocorticoids should be restarted and tapered more slowly.

Special circumstances — Occasionally, a medication that caused serum sickness and for which there is no reasonable alternative either cannot be discontinued or is needed again in the future.

Agents that cannot be stopped — In rare situations, the offending agent is lifesaving and may need to be continued while serum sickness is treated symptomatically. In animal models of chronic serum sickness, in which intermittent injections of foreign proteins were repeated over time, fatal renal failure developed in some animals [84]. However, favorable outcomes have been reported in humans in this situation. As an example, anti-thymocyte globulin (ATG) is used in the treatment of patients with aplastic anemia, and it is sometimes continued in the setting of serum sickness because the therapy is potentially curative. (See "Treatment of aplastic anemia in adults", section on 'Management of toxicities'.)

In other situations, plasmapheresis has been used to treat or prevent recurrent serum-sickness attacks when implicating agents could not be discontinued, although this approach would be appropriate only if the therapeutic agent is not primarily present in the circulation, since apheresis would also remove the therapy [85].

Retreatment protocols — Retreatment protocols based on gradual dose escalation have been reported for the management of oncology patients who developed SSLRs in response to rituximab but required ongoing therapy [25,86-88]. Best documented are cases involving retreatment with rituximab, an anti-B cell monoclonal, in patients with lymphomas [86-88]. Most reactive patients had a broad hypersensitivity syndrome, which included signs and symptoms of mast cell activation, in many cases associated with positive immunoglobulin E (IgE) skin testing, a type of reaction that should be amenable to desensitization. Whether other patients with isolated SSLRs to rituximab or other foreign proteins can be "desensitized" remains to be demonstrated. Referral to an allergy specialist with expertise in drug allergy is suggested if this approach were under consideration.

PREVENTING RECURRENCE — Once serum sickness or SSLRs develop, the drug that is responsible should be avoided, if possible. This should be recorded in the patient's medical record, and the patient should be educated about the various names the culprit drug might have. If the drug is commonly encountered, the patient should obtain a medical identification bracelet or necklace. After an episode of serum sickness, re-exposure to the same drug may lead to a more rapid and more severe serum-sickness reaction. (See 'Temporal course' above.)

If no alternative agents are available and retreating with a drug that previously caused serum sickness is absolutely required, treatment with antihistamines or glucocorticoids may help prevent future episodes of serum sickness upon re-exposure [49].

Future use of related drugs — There is some controversy about whether related drugs can be used safely in a patient with a past serum sickness or SSLR to a specific agent. As an example, after cefaclor-induced SSLRs, administration of another cephalosporin is usually well-tolerated, and there are case reports of patients tolerating cefazolin following a SSLR to nafcillin [89]. However, some authorities recommend that all beta-lactam drugs be avoided when possible [18,82].

Neither skin tests nor any in vitro studies are able to predict initial or recurrent episodes of serum sickness [57,90].

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Drug allergy".)


Classic "serum sickness" describes the clinical syndrome caused by immunization of the host (human) by heterologous (nonhuman) serum proteins and subsequent illness caused by formation of immune complexes. Serum sickness-like reactions (SSLRs) present as rash, arthritis, and fever beginning several days to weeks following administration of a drug. (See 'Introduction' above.)

Classic serum sickness is a Gell and Coombs "type III" or immune complex-mediated hypersensitivity disease (table 1). Heterologous protein antigens combine with host immunoglobulins specifically reacting with those antigens. If the resultant immune complexes are not adequately cleared by the mononuclear phagocyte system, excess immune complexes form in (or are deposited in) tissues and trigger an inflammatory response. In contrast, the pathophysiology of SSLRs is less well-characterized and may vary depending upon the culprit agent. (See 'Pathophysiology' above.)

A variety of heterologous "foreign" proteins can cause classic serum sickness (table 2). Therapeutic murine monoclonal antibodies and chimeric antibodies, including equine anti-thymocyte globulin (ATG), rituximab, and infliximab, have been implicated. SSLRs are most commonly caused by antibiotics, such as penicillin, cefaclor, amoxicillin, and trimethoprim-sulfamethoxazole, although a variety of medications have been associated with these reactions (table 3). (See 'Etiology and epidemiology' above.)

The most common symptoms of serum sickness are rash, fever, malaise, and polyarthralgias or polyarthritis, which occur one to two weeks after first exposure to the responsible agent and resolve within a few weeks of discontinuing the drug. In patients who have been previously exposed to the agent, the syndrome starts earlier (ie, within one to seven days of receiving the inciting agent), and the illness has a more severe and "explosive" onset. The rash is a pruritic urticarial and/or morbilliform eruption. The mucosal membranes are not involved. Laboratory findings are variable. (See 'Clinical manifestations' above and 'Evaluation' above.)

The diagnosis of serum sickness and SSLRs is made clinically, based upon the characteristic pattern of physical and laboratory findings occurring after exposure to a potential offending agent. (See 'Diagnosis' above.)

The management of these reactions primarily involves discontinuation of possible culprit agents. Typically, fever and arthralgias resolve and new skin lesions stop forming within 48 hours of this intervention. This is often all that is required for patients with mild symptoms. (See 'Withdrawal of culprit agent' above.)

Further treatments depend upon the discomfort of the individual patient. Antihistamines may be administered for symptomatic relief of pruritus. Nonsteroidal anti-inflammatory agents and analgesics may be given for symptomatic treatment of low-grade fever and arthralgias. (See 'Symptomatic treatment' above.)

For patients with higher fever (eg, temperature >38.5°C [>101.3°F]), more severe arthritis and arthralgias, or extensive rashes, we suggest short courses of glucocorticoids (Grade 2C). These are usually administered orally (eg, prednisone at 0.5 to 1 mg/kg per day), although intravenous administration (methylprednisolone in the range of 1 to 2 mg/kg per day in one or two divided doses) may be considered in patients who appear acutely ill. This treatment can usually be tapered within the course of one week. (See 'Glucocorticoids' above.)

Once serum sickness or SSLRs develop, the responsible drug should be avoided in the future. Recurrent reactions can be more severe and develop more quickly. It is not clear that similar drugs must also be avoided, although that is the safest approach if there are alternative drugs that could be used instead. (See 'Preventing recurrence' above.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. von Pirquet CF, Schick B. (Die Serumkrankheit). Serum Sickness, Schick B (Ed), Williams & Wilkins, Leipzig 1905 (translation Baltimore 1951).
  2. Lawley TJ, Bielory L, Gascon P, et al. A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med 1984; 311:1407.
  3. Vincent C, Revillard JP. Antibody response to horse gamma-globulin in recipients of renal allografts: relationship with transplant crises and transplant survival. Transplantation 1977; 24:141.
  4. Bielory L, Yancey KB, Young NS, et al. Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin. J Am Acad Dermatol 1985; 13:411.
  5. Bielory L, Gascon P, Lawley TJ, et al. Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine (Baltimore) 1988; 67:40.
  6. Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 1994; 265:1095.
  7. Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279:1052.
  8. Sylvestre D, Clynes R, Ma M, et al. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med 1996; 184:2385.
  9. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16:421.
  10. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275.
  11. Apisarnthanarak A, Uyeki TM, Miller ER, Mundy LM. Serum sickness-like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes. Clin Infect Dis 2009; 49:e18.
  12. Arkachaisri T. Serum sickness and hepatitis B vaccine including review of the literature. J Med Assoc Thai 2002; 85 Suppl 2:S607.
  13. Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125:805.
  14. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356:1587.
  15. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24:477.
  16. Zhang Z, Xiang Y, Wang B, et al. Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions. Eur J Pediatr 2013; 172:537.
  17. Kunnamo I, Kallio P, Pelkonen P, Viander M. Serum-sickness-like disease is a common cause of acute arthritis in children. Acta Paediatr Scand 1986; 75:964.
  18. Vial T, Pont J, Pham E, et al. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother 1992; 26:910.
  19. Lieberman P, Rice MC, Mallette JE Jr. Studies of urticaria and acute serum sickness with the C1q precipitin test. Arch Intern Med 1977; 137:440.
  20. Boothpur R, Hardinger KL, Skelton RM, et al. Serum sickness after treatment with rabbit antithymocyte globulin in kidney transplant recipients with previous rabbit exposure. Am J Kidney Dis 2010; 55:141.
  21. Schaeffer TH, Khatri V, Reifler LM, Lavonas EJ. Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis. Acad Emerg Med 2012; 19:121.
  22. Mong R, Ng VCH, Tse ML. Safety profile of snake antivenom (use) in Hong Kong - a review of 191 cases from 2008 to 2015. Clin Toxicol (Phila) 2017; 55:1066.
  23. Ryan NM, Kearney RT, Brown SG, Isbister GK. Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22). Clin Toxicol (Phila) 2016; 54:27.
  24. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542.
  25. Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheum 2015; 45:334.
  26. Tanriover B, Chuang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation 2005; 80:279.
  27. Rana JS, Sheikh J. Serum sickness-like reactions after placement of sirolimus-eluting stents. Ann Allergy Asthma Immunol 2007; 98:201.
  28. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325.
  29. Hamzaoglu H, Cooper J, Alsahli M, et al. Safety of infliximab in Crohn's disease: a large single-center experience. Inflamm Bowel Dis 2010; 16:2109.
  30. Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009; 23:101.
  31. Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120:972.
  32. Abu-Elmagd KM, Costa G, Bond GJ, et al. A decade of experience with a single dose of rabbit antithymocyte globulin or alemtuzumab pretreatment for intestinal and multivisceral transplantation. Clin Transpl 2012; :155.
  33. Krumbholz M, Pellkofer H, Gold R, et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64:1331.
  34. Russo EA, Iacucci M, Lindsay JO, et al. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol 2010; 22:334.
  35. Saba J, Logan AC. Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia. Clin Case Rep 2017; 5:891.
  36. Saegeman V, Wynendaele W, Kerre S, et al. Transfusion-induced serum sickness. Transfusion 2009; 49:372.
  37. Reisman RE, Livingston A. Late-onset allergic reactions, including serum sickness, after insect stings. J Allergy Clin Immunol 1989; 84:331.
  38. Gaig P, García-Ortega P, Enrique E, et al. Serum sickness-like syndrome due to mosquito bite. J Investig Allergol Clin Immunol 1999; 9:190.
  39. Bonds RS, Kelly BC. Severe serum sickness after H1N1 influenza vaccination. Am J Med Sci 2013; 345:412.
  40. Warrington RJ, Martens CJ, Rubin M, et al. Immunologic studies in subjects with a serum sickness-like illness after immunization with human diploid cell rabies vaccine. J Allergy Clin Immunol 1987; 79:605.
  41. Wise RP, Iskander J, Pratt RD, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 2004; 292:1702.
  42. Milstien JB, Gross TP, Kuritsky JN. Adverse reactions reported following receipt of Haemophilus influenzae type b vaccine: an analysis after 1 year of marketing. Pediatrics 1987; 80:270.
  43. Cruz NV, Bahna SL. Fever, urticaria, lymphadenopathy, and protracted arthralgia and myalgia resistant to corticosteroid therapy. Allergy Asthma Proc 2011; 32:395.
  44. Hunt KJ, Sobotka AK, Valentine MD, et al. Sensitization following Hymenoptera whole body extract therapy. J Allergy Clin Immunol 1978; 61:48.
  45. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69:567.
  46. Borden J, Fonkalsrud E, Newcomer V. Snake bite: treatment by isolation perfusion technique. Surgery 1961; 49:303.
  47. Morales C, Brasó JV, Pellicer A, et al. Serum sickness due to bovine serum albumin sensitization during in vitro fertilization. J Investig Allergol Clin Immunol 1994; 4:246.
  48. Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13:94.
  49. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97:1408.
  50. LoVecchio F, Welch S, Klemens J, et al. Incidence of immediate and delayed hypersensitivity to Centruroides antivenom. Ann Emerg Med 1999; 34:615.
  51. Kunkel DB, Curry SC, Vance MV, Ryan PJ. Reptile envenomations. J Toxicol Clin Toxicol 1983- 1984; 21:503.
  52. Shemesh IY, Kristal C, Langerman L, Bourvin A. Preliminary evaluation of Vipera palaestinae snake bite treatment in accordance to the severity of the clinical syndrome. Toxicon 1998; 36:867.
  53. Jurkovich GJ, Luterman A, McCullar K, et al. Complications of Crotalidae antivenin therapy. J Trauma 1988; 28:1032.
  54. Vozianova ZhI, Chepilko KI. [Serum sickness in diphtheria]. Lik Sprava 1999; :126.
  55. Suwansrinon K, Jaijareonsup W, Wilde H, et al. Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg 2007; 101:206.
  56. Sène D, Ghillani-Dalbin P, Amoura Z, et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009; 60:3848.
  57. Tantawichien T, Benjavongkulchai M, Wilde H, et al. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin Infect Dis 1995; 21:660.
  58. Dart RC, McNally J. Efficacy, safety, and use of snake antivenoms in the United States. Ann Emerg Med 2001; 37:181.
  59. Dart RC, Seifert SA, Boyer LV, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med 2001; 161:2030.
  60. Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002; 39:671.
  61. Clark BM, Kotti GH, Shah AD, Conger NG. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy 2006; 26:705.
  62. Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol 2006; 6:3.
  63. Tatum AJ, Ditto AM, Patterson R. Severe serum sickness-like reaction to oral penicillin drugs: three case reports. Ann Allergy Asthma Immunol 2001; 86:330.
  64. Misirlioglu ED, Duman H, Ozmen S, Bostanci I. Serum sickness-like reaction in children due to cefditoren. Pediatr Dermatol 2012; 29:327.
  65. Swanson JK, English JC 3rd. Serum sickness-like reaction to Pamabrom. J Drugs Dermatol 2006; 5:284.
  66. Ferguson P. Case Report: Glatiramer Acetate-Induced Serum Sickness. Int J MS Care 2017; 19:263.
  67. Heckbert SR, Stryker WS, Coltin KL, et al. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol 1990; 132:336.
  68. Stricker BH, Tijssen JG. Serum sickness-like reactions to cefaclor. J Clin Epidemiol 1992; 45:1177.
  69. King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health 2003; 39:677.
  70. Fishbein DB, Yenne KM, Dreesen DW, et al. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine 1993; 11:1390.
  71. Swanson MC, Rosanoff E, Gurwith M, et al. IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis 1987; 155:909.
  72. Anderson MC, Baer H, Frazier DJ, Quinnan GV. The role of specific IgE and beta-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine. J Allergy Clin Immunol 1987; 80:861.
  73. Dreesen DW, Bernard KW, Parker RA, et al. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine. Vaccine 1986; 4:45.
  74. Chiong FJ, Loewenthal M, Boyle M, Attia J. Serum sickness-like reaction after influenza vaccination. BMJ Case Rep 2015; 2015.
  75. Hengge UR, Scharf RE, Kroon FP, Pfeffer K. Severe serum sickness following pneumococcal vaccination in an AIDS patient. Int J STD AIDS 2006; 17:210.
  76. Yorulmaz A, Akın F, Sert A, et al. Demographic and clinical characteristics of patients with serum sickness-like reaction. Clin Rheumatol 2017.
  77. Nguyen CV, Miller DD. Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern. J Cutan Pathol 2017; 44:177.
  78. Starnes L, Patel T, Skinner RB. Urticaria multiforme--a case report. Pediatr Dermatol 2011; 28:436.
  79. Shah KN, Honig PJ, Yan AC. "Urticaria multiforme": a case series and review of acute annular urticarial hypersensitivity syndromes in children. Pediatrics 2007; 119:e1177.
  80. Emer JJ, Bernardo SG, Kovalerchik O, Ahmad M. Urticaria multiforme. J Clin Aesthet Dermatol 2013; 6:34.
  81. Joubert GI, Hadad K, Matsui D, et al. Selection of treatment of cefaclor-associated urticarial, serum sickness-like reactions and erythema multiforme by emergency pediatricians: lack of a uniform standard of care. Can J Clin Pharmacol 1999; 6:197.
  82. Grammer LC. Cefaclor serum sickness. JAMA 1996; 275:1152.
  83. Lundquist AL, Chari RS, Wood JH, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007; 13:647.
  84. Wilson CB, Dixon FJ. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med 1971; 134:7s.
  85. Bayraktar F, Akinci B, Demirkan F, et al. Serum sickness-like reactions associated with type III insulin allergy responding to plasmapheresis. Diabet Med 2009; 26:659.
  86. Fajt ML, Petrov AA. Desensitization protocol for rituximab-induced serum sickness. Curr Drug Saf 2014; 9:240.
  87. Wong JT, Long A. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms. J Allergy Clin Immunol Pract 2017; 5:1564.
  88. Isoda A, Ishikawa T, Sato N, et al. Repeated rituximab-induced serum sickness with anaphylaxis. Rinsho Ketsueki 2016; 57:771.
  89. Blumenthal KG, Youngster I, Shenoy ES, et al. Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting. Antimicrob Agents Chemother 2014; 58:3137.
  90. Erffmeyer JE. Serum sickness. Ann Allergy 1986; 56:105.
Topic 2078 Version 15.0